Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Vaccines
Sanofi ditches mRNA vaccine for COVID-19
by Ryan Cross
October 1, 2021
| A version of this story appeared in
Volume 99, Issue 36
Just 2 months after agreeing to spend $3.2 billion to acquire Translate Bio, Sanofi says it will stop developing Translate’s messenger RNA (mRNA) vaccine for COVID-19. Although the vaccine looked promising in its Phase 1/2 clinical trial, Sanofi says it doubts that it would be able to finish tests of the shot in time to help with the pandemic. Instead, the firm will focus on developing mRNA vaccines for the flu and other diseases. Sanofi will also continue developing its own protein-based vaccine for COVID-19, which is in a Phase 3 trial.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X